Poster 1014: Omalizumab efficiency in patients with allergic rhinitis and chronic sinusitis by Sandra Gonzalez-Diaz & Lorena Rangel-Garza
POSTER PRESENTATION Open Access
Poster 1014: Omalizumab efficiency in patients
with allergic rhinitis and chronic sinusitis
Sandra Nora Gonzalez-Diaz1, Lorena Rangel-Garza2*
From 2013 WAO Symposium on Immunotherapy and Biologics
Chicago, IL, USA. 13-14 December 2013
Background
Allergic rhinitis (AR) is a very common chronic respira-
tory disorder and has also been shown to negatively
impact quality of life with many comorbiliditys like
Chronic rhinosinusitis; There is evidence that IgE antibo-
dies play a role in chronic sinusitis. Investigations have
shown that total IgE levels correlate with the severity of
sinusitis, as assessed by CT scan. Allergies occur more fre-
quently in patients with chronic sinusitis than in the gen-
eral population. Omalizumab has shown to be effective for
AR in allergen challenge studies and clinical trials. Multi-
ple randomized, double-blind, placebo-controlled studies
have shown efficacy of omalizumab in seasonal and peren-
nial AR.
Methods
All patients form private consult with AR who also had
chronic rhinosinusitis in which symptoms were evaluated
using the analog visual scale (VAS) at the beginning of
their medical treatment. All subjects included in this study
had skin prick positive tests to multiple aeroallergens and
food without improvement of their symptoms after one
year of specific subcutaneous immunotherapy to whom
posterior Omalizumab of 150 to 300 mg was admini-
strated every 4 weeks at least for one year and who were
evaluated again using the analog visual scale at the end of
their treatment.
Results
11 patients were included, 6 females, 1 of them with rhi-
nosinusitis and nasal polyps (CRSwNP) and 5 males. Ages
were from 7 to 71 years (34.5 years average). The analog
visual scale at the beginning had and average of 4.5 points
and after a year with Omalizumab scores increased to an
average of 8.3 points with an increase of 3.8 points. The
only patient with chronic rhinosinusitis and nasal polyps
(CRSwNP) presented polyps remission with an improve-
ment of life quality. None of the patients presented severe
adverse reactions from the application of Omalizumab.
Conclusions
Clinical improvement was found and omalizumab could
be considered of benefit in patients with chronic rhinosi-
nusitis who also has proved to be secured
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